In this work, we consolidated genomic and clinical ICI data of melanoma and non-small cell lung cancer (NSCLC) samples, noticed that FASN mutations were linked to an elevated antitumor immunity, and were predictive of an improved ICI prognosis outcome and immunotherapeutic response rate. This evidence concerns the gene FASN and non-small cell lung carcinoma.